The criteria for inclusion encompassed: (a) malignancies from solid organs except gynecological cancers, (b) ICI treatment agents were referring to three major classes: PD-1 inhibitors, PD-L1 inhibitors, CTLA4- inhibitors, or their combinations, and (c) any CV toxicity classified into nine major categories: myocarditis, pericardial disease, arrhythmias, cardiac failure, Takotsubo cardiomyopathy, ischemic heart disease, heart valve disease, venous thromboembolism, artery disease [16]. This evidence concerns the gene PDCD1 and heart failure.